^
Association details:
| Biomarker: | ABL1 F359V |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Resistance To Dasatinib In Philadelphia-Positive Leukemia Patients And The Presence Or The Selection Of Mutations At Residues 315 And 317 In The BCR-ABL Kinase Domain
Excerpt:
Thirteen patients had acquired resistance to dasatinib (patients #9–21 in Table 1 and Figure 1). Relapse occurred a median of 7 months (range, 3–15) after starting dasatinib. Mutation analysis performed before the onset of treatment showed that five of these patients had no evidence of nucleotide changes, while the remaining eight patients harbored various imatinib-resistant kinase domain mutations (G250E, Y253H, E255K, D276G, M351T, L387M; Table 1 and Figure 1).
DOI:
10.3324/haematol.10822
